...
首页> 外文期刊>Endocrine. >Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis
【24h】

Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis

机译:降压药,骨矿物质密度和骨折:旧的心脏药物的综述为骨质疏松症提供了新的见解

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Osteoporosis is increasing in prevalence and importance as society's age, with the clinical consequence of fractures of the hip, spine, and upper extremity, leading to impaired quality of life, loss of function and independence, and increased morbidity and mortality. A major risk factor for osteoporosis is older age, and cardiovascular diseases also share this risk factor; therefore, osteoporosis and cardiovascular disease often coexist and share risk factors. Medications used for the treatment of cardiovascular diseases, in particular antihypertensive drugs, have been shown in a variety of studies of varying designs to modulate bone health in both a positive or negative manner. In this article, we reviewed the pharmacology, potential mechanisms, and possible effects on bone mineral density and fracture risk of commonly prescribed antihypertensive medications, including thiazide and non-thiazide diuretics, beta-blockers, calcium channel blockers, renin-angiotensin-aldosterone system agents, and nitrates.
机译:随着社会年龄的增长,骨质疏松症的患病率和重要性正在上升,其临床后果是髋部,脊柱和上肢骨折,从而导致生活质量受损,功能丧失和独立性以及发病率和死亡率增加。骨质疏松症的主要危险因素是年龄大,心血管疾病也有此危险因素。因此,骨质疏松症和心血管疾病通常并存并共享危险因素。在各种设计以正向或负向调节骨骼健康的研究中,已经显示出用于治疗心血管疾病的药物,特别是降压药。在本文中,我们回顾了常用处方降压药(包括噻嗪类和非噻嗪类利尿剂,β-受体阻滞剂,钙通道阻滞剂,肾素-血管紧张素-醛固酮系统)的药理作用,潜在机理以及对骨矿物质密度和骨折风险的可能影响剂和硝酸盐。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号